



More patients need the precision of cardiac PET

Cardiac PET MPI delivers diagnostic accuracy for today's and tomorrow's growing patient populations.²⁻⁵

Medical societies recommend PET MPI for^{3,4}:

- Challenging-to-image body types (e.g., BMI >35, dense breasts, or implants)
- Patients who are high risk, where diagnostic errors have greater clinical implications (e.g., diabetes)



PET = Positron emission tomography; MPI = Myocardial perfusion imaging;
BMI = Body mass index; SPECT = Single photon emission computed tomography.



By 2060, there is a
17% to 39%

average projected increase
in cardiovascular (CV) risk
factors and disease^{1*}

**Cardiac PET MPI is superior to SPECT
for many growing populations with
CV risk factors and disease²⁻⁵:**

Patients with **hypertension**—
61% of the population by 2050

Patients with **obesity**—
60.6% of the population by 2050

Patients with **diabetes**—
26.8% of the population by 2050



Did you know?

Cardiac PET MPI is
recommended for women^{3,4,6}—
half the general population.

Discover the benefits of cardiac PET with Flyrcado



Long half-life

A 109-minute half-life enables flexible protocols, including exercise or pharmacologic stress and reimaging[†] if needed.^{6,7}



Convenient unit dose delivery

Order as needed, with no patient volume minimums—no on-site generator or cyclotron required.^{7,9}



Exceptional image quality

High extraction fraction and short positron range yield excellent resolution.⁷



Greater diagnostic certainty vs. SPECT

Reliable CAD detection in overall population and difficult-to-image patients.^{2-4,8}



GE HealthCare expertise

Comprehensive services and training to support your needs.

IMPORTANT SAFETY INFORMATION

FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use

Indications and Usage

FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

Contraindications

None

Radiation Risks

FLYRCADO contributes to cumulative radiation exposure, which is associated with an increased risk of cancer. Handle safely to minimize exposure for patients and staff.

Advise patients to hydrate before and after administration and to void frequently.

Adverse Reactions

Most common adverse reactions (≥2%) include dyspnea, headache, angina pectoris, chest pain, fatigue, ST-segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

Use in Specific Populations

Pregnancy: No human data are available. Counsel patients about potential fetal risks related to radiation and ethanol exposure (contains up to 337 mg anhydrous ethanol).

Lactation: Advise women to pump and discard breast milk for at least 8 hours after administration.

Pediatric Use: Safety and effectiveness have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2, then option 1) or by e-mail at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or www.fda.gov/medwatch.

See how clarity
in Anthony's
case **changed**
care decisions.

The image shown is a model and not a real patient.

Clinical case: Chest pain revealed hidden danger

67-year-old retired bus driver who developed chest pain when climbing stairs. Risk factors included diabetes, obesity, smoking, peripheral artery disease (PAD), and an abdominal aortic aneurysm.



Scan to read Anthony's case study and see how PET with Flyrcado helped him.

CAD = Coronary artery disease; PAD = Peripheral artery disease.

*Risk factors include: diabetes, hypertension, dyslipidemia, and obesity.

Cardiovascular disease includes: ischemic heart disease, heart failure, myocardial infarction, and stroke. †Allows for repeat imaging (static imaging, not dynamic) within 25 minutes from injection in the event of technical difficulties (e.g., patient motion), without additional dosing or radiation exposure.

References: 1. Mohebi R, Chen C, Ibrahim NE, et al. Cardiovascular disease projections in the United States based on the 2020 census estimates. *J Am Coll Cardiol*. 2022;80(6):565-578. 2. Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET myocardial perfusion imaging in patients with suspected coronary artery disease. *J Am Coll Cardiol*. 2023;82(16):1598-1610. 3. Schindler TH, Bateman TM, Berman DS, et al. Appropriate use criteria for PET myocardial perfusion imaging. *J Nucl Med*. 2020;61(8):1221-1265. 4. Bateman TM, Dilsizian V, Beanlands RS, DePuey EG, Heller GV, Wolinsky DA. American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging joint position statement on the clinical indications for myocardial perfusion PET. *J Nucl Med*. 2016;57(10):1654-1656. 5. Joynt KE, Elkind MSV, Aparicio HJ, et al. Forecasting the burden of cardiovascular disease and stroke in the United States through 2050—prevalence of risk factors and disease: a presidential advisory from the American Heart Association. *Circulation*. 2024;150(4):e65–e88. doi:<https://doi.org/10.1161/cir.0000000000001256>. 6. Patel KK, Singh A, Bateman TM. The potential of F-18 flurpiridaz PET/CT myocardial perfusion imaging for precision imaging. *Curr Cardiol Rep*. 2022;24(8):987-994. 7. Maddahi J, Packard RRS. Cardiac PET perfusion tracers: current status and future directions. *Semin Nucl Med*. 2014;44(5):333-343. 8. Flyrcado (flurpiridaz F 18 injection). Full Prescribing Information. Marlborough, MA: GE HealthCare. 9. Iskandrian AE, Dilsizian V, Garcia EV, et al. Myocardial perfusion imaging: lessons learned and work to be done—update. *J Nucl Cardiol*. 2018;25(1):39-52.



Scan the QR code to view
full Prescribing Information.

© 2026 GE HealthCare. Flyrcado is a trademark of GE HealthCare. GE is a trademark of General Electric Company used under trademark license. January 2026 | JB13038US



GE HealthCare